MEI Pharma, Inc. Rebrands as Lite Strategy, Inc., Adopts New NASDAQ Ticker ‘LITS’
Read moreMEI Pharma Acquires Litecoin, Launches $100M Institutional Treasury Strategy with Charlie Lee and GSR Advising
Read moreMEI Pharma Announces Closing of $100,000,000 Private Placement to Initiate Litecoin Treasury Strategy, Becoming First and Only Publicly Traded LTC Holder on a National Exchange
Read moreOncology Focused, Patient Centric
We are committed to the development of novel and differentiated cancer therapies intended to overcome known drug resistance mechanisms in combination with standard-of-care therapies to provide improved outcomes to patients.
